Commonalities in the genetics of Alzheimer’s disease and Parkinson’s disease

References

• Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med.1(1), e27 (2004).
   PubMedGoogle Scholar
• Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch. Neurol.57(3), 418–420 (2000).
   PubMed Web of Science ®Google Scholar
• Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J.27(2), 336–349 (2008).
   PubMed Web of Science ®Google Scholar
• Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N. Engl. J. Med.348(14), 1356–1364 (2003).
   PubMed Web of Science ®Google Scholar
• Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clin. Anat.8(6), 429–431 (1995).
   PubMedGoogle Scholar
• Clarck C, Ewbank D, Lee V-Y, Trojanowski JQ. Molecular pathology of Alzheimer’s disease: neuronal cytoskeletal abnormalities. In: The Dementias. Growdon J, Rossor MN (Eds). Butterworth–Heinemann, Boston, MA, USA (1998).
   Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology17(5), 427–442 (1967).
   PubMed Web of Science ®Google Scholar
• Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol.52(3), 183–191 (1993).
   PubMed Web of Science ®Google Scholar
• Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann. Neurol.7(4), 329–335 (1980).
   PubMed Web of Science ®Google Scholar
• Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol.64(1), 43–52 (1984).
   PubMed Web of Science ®Google Scholar
• Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases. Free Radic. Biol. Med.32(12), 1264–1275 (2002).
   PubMed Web of Science ®Google Scholar
• Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson’s disease. Mov. Disord.14(6), 928–939 (1999).
   PubMed Web of Science ®Google Scholar
• Grünblatt E, Zehetmayer S, Bartl J et al. Genetic risk factors and markers for Alzheimer’s disease and/or depression in the VITA study. J. Psychiatr. Res. DOI: 10.1016/j.jpsychires.2008.05.008 (2008) (Epub ahead of print).
   Google Scholar
• Fischer P, Zehetmayer S, Jungwirth S et al. Risk factors for Alzheimer dementia in a community-based birth cohort at the age of 75 years. Dement. Geriatr. Cogn. Disord.25(6), 501–507 (2008).
   PubMedGoogle Scholar
• Stozicka Z, Zilka N, Novak M. Risk and protective factors for sporadic Alzheimer’s disease. Acta Virol.51(4), 205–222 (2007).
   PubMedGoogle Scholar
• Berg D. Biomarkers for the early detection of Parkinson’s and Alzheimer’s disease. Neurodegener. Dis.5(3–4), 133–136 (2008).
   PubMedGoogle Scholar
• Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson’s disease. Parkinsonism Relat. Disord.9(Suppl. 2), S83–S89 (2003).
   Web of Science ®Google Scholar
• Schweitzer I, Tuckwell V, O’Brien J, Ames D. Is late onset depression a prodrome to dementia? Int. J. Geriatr. Psychiatry17(11), 997–1005 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkes C. Olfaction in neurodegenerative disorder. Mov. Disord.18(4), 364–372 (2003).
   PubMed Web of Science ®Google Scholar
• Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann. Neurol.63(1), 7–15 (2008).
   PubMed Web of Science ®Google Scholar
• Coppede F, Mancuso M, Siciliano G, Migliore L, Murri L. Genes and the environment in neurodegeneration. Biosci. Rep.26(5), 341–367 (2006).
   PubMed Web of Science ®Google Scholar
• Allam MF, Del Castillo AS, Navajas RF. Parkinson’s disease risk factors: genetic, environmental, or both? Neurol. Res.27(2), 206–208 (2005).
   PubMed Web of Science ®Google Scholar
• Elbaz A, Dufouil C, Alperovitch A. Interaction between genes and environment in neurodegenerative diseases. C R Biol.330(4), 318–328 (2007).
   PubMed Web of Science ®Google Scholar
• Zandi PP, Carlson MC, Plassman BL et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA288(17), 2123–2129 (2002).
   PubMed Web of Science ®Google Scholar
• Hoyer S, Riederer P. Alzheimer disease – no target for statin treatment. A mini review. Neurochem. Res.32(4–5), 695–706 (2007).
   PubMedGoogle Scholar
• Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer’s disease. Am. J. Geriatr. Cardiol.16(3), 143–149 (2007).
   PubMedGoogle Scholar
• Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch. Neurol.64(1), 93–96 (2007).
   PubMedGoogle Scholar
• Holmes C. Genotype and phenotype in Alzheimer’s disease. Br. J. Psychiatry180, 131–134 (2002).
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH. Genetics of Parkinson’s disease. Ann. NY Acad. Sci.920, 28–32 (2000).
   PubMedGoogle Scholar
• Hol EM, van Leeuwen FW, Fischer DF. The proteasome in Alzheimer’s disease and Parkinson’s disease: lessons from ubiquitin B+1. Trends Mol. Med.11(11), 488–495 (2005).
   PubMed Web of Science ®Google Scholar
• Shi Q, Tao E. An Ile93Met substitution in the UCH-L1 gene is not a disease-causing mutation for idiopathic Parkinson’s disease. Chin. Med. J. (Engl.)116(2), 312–313 (2003).
   PubMedGoogle Scholar
• Lambert JC, Amouyel P. Genetic heterogeneity of Alzheimer’s disease: complexity and advances. Psychoneuroendocrinology32(Suppl. 1), S62–S70 (2007).
   PubMed Web of Science ®Google Scholar
• Pankratz N, Byder L, Halter C et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson’s disease and a higher risk with dementia. Mov. Disord.21(1), 45–49 (2006).
   PubMed Web of Science ®Google Scholar
• Wider C, Wszolek ZK. Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies. Neurodegener. Dis.5(3–4), 122–125 (2008).
   PubMedGoogle Scholar
• Tobin JE, Latourelle JC, Lew MF et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology71(1), 28–34 (2008).
   PubMedGoogle Scholar
• Pankratz N, Foroud T. Genetics of Parkinson disease. Genet. Med.9(12), 801–811 (2007).
   PubMed Web of Science ®Google Scholar
• Randall CN, Strasburger D, Prozonic J et al. Cluster analysis of risk factor genetic polymorphisms in Alzheimer’s disease. Neurochem. Res. DOI: 10.1007/s11064-008-9626-8 (2008) (Epub ahead of print).
   Google Scholar
• Mukherjee O, Kauwe JS, Mayo K, Morris JC, Goate AM. Haplotype-based association analysis of the MAPT locus in late onset Alzheimer’s disease. BMC Genet.8, 3 (2007).
   PubMed Web of Science ®Google Scholar
• Laws SM, Friedrich P, Diehl-Schmid J et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer’s disease. Mol. Psychiatry12(5), 510–517 (2007).
   PubMed Web of Science ®Google Scholar
• Morris HR, Steele JC, Crook R et al. Genome-wide analysis of the parkinsonism–dementia complex of Guam. Arch. Neurol.61(12), 1889–1897 (2004).
   PubMed Web of Science ®Google Scholar
• Sillen A, Forsell C, Lilius L et al. Genome scan on Swedish Alzheimer’s disease families. Mol. Psychiatry11(2), 182–186 (2006).
   PubMedGoogle Scholar
• Grupe A, Abraham R, Li Y et al. Evidence for novel susceptibility genes for late-onset Alzheimer’s disease from a genome-wide association study of putative functional variants. Hum. Mol. Genet.16(8), 865–873 (2007).
   PubMed Web of Science ®Google Scholar
• Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch. Neurol.65(3), 329–334 (2008).
   PubMedGoogle Scholar
• Foltynie T, Hicks A, Sawcer S et al. A genome wide linkage disequilibrium screen in Parkinson’s disease. J. Neurol.252(5), 597–602 (2005).
   PubMedGoogle Scholar
• Fung HC, Scholz S, Matarin M et al. Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol.5(11), 911–916 (2006).
   PubMed Web of Science ®Google Scholar
• Price AL, Butler J, Patterson N et al. Discerning the ancestry of European Americans in genetic association studies. PLoS Genet.4(1), e236 (2008).
   PubMed Web of Science ®Google Scholar
• Scheet P, Stephens M. Linkage disequilibrium-based quality control for large-scale genetic studies. PLoS Genet.4(8), e1000147 (2008).
   Google Scholar
• Zhang W, Duan S, Dolan ME. HapMap filter 1.0: a tool to preprocess the HapMap genotypic data for association studies. Bioinformation2(8), 322–324 (2008).
   PubMedGoogle Scholar
• Grünblatt E, Zander N, Bartl J et al. Comparison analysis of gene expression patterns between sporadic Alzheimer’s and Parkinson’s disease. J. Alzheimers Dis.12(4), 291–311 (2007).
   PubMed Web of Science ®Google Scholar
• Pasinetti GM. Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer’s disease dementia. J. Neurosci. Res.65(6), 471–476 (2001).
   PubMedGoogle Scholar
• Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and proinflammatory signaling. J. Neurosci. Res.70(3), 462–473 (2002).
   PubMed Web of Science ®Google Scholar
• Yao PJ, Zhu M, Pyun EI et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer’s disease. Neurobiol. Dis.12(2), 97–109 (2003).
   PubMed Web of Science ®Google Scholar
• Grünblatt E, Mandel S, Jacob-Hirsch J et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm.111(12), 1543–1573 (2004).
   PubMed Web of Science ®Google Scholar
• Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet.14(13), 1709–1725 (2005).
   PubMed Web of Science ®Google Scholar
• Hauser MA, Li YJ, Xu H et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch. Neurol.62(6), 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Ffrench-Mullen J, McCorquodale D, Qin Y, Pablo J, Mash DC. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson’s disease. Gene Expr.13(3), 205–215 (2006).
   PubMed Web of Science ®Google Scholar
• Li YJ, Oliveira SA, Xu P et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum. Mol. Genet.12(24), 3259–3267 (2003).
   PubMed Web of Science ®Google Scholar
• Li YJ, Scott WK, Zhang L et al. Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases. Neurobiol. Aging27(8), 1087–1093 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Pastene C, Graumann R, Diaz-Grez F et al. Association of GST M1 null polymorphism with Parkinson’s disease in a Chilean population with a strong Amerindian genetic component. Neurosci. Lett.418(2), 181–185 (2007).
   PubMed Web of Science ®Google Scholar
• Vilar R, Coelho H, Rodrigues E et al. Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson’s disease. Eur. J. Neurol.14(2), 156–161 (2007).
   PubMedGoogle Scholar
• Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J. Biomed. Biotechnol.2(3), 120–123 (2002).
   PubMedGoogle Scholar
• Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson’s disease: is there a causal link? Exp. Neurol.193(2), 279–290 (2005).
   PubMed Web of Science ®Google Scholar
• Smith MT, Sandy MS, Di Monte D. Free radicals, lipid peroxidation, and Parkinson’s disease. Lancet1(8523), 38 (1987).
   PubMedGoogle Scholar
• Smith CD, Carney JM, Starke-Reed PE et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl Acad. Sci. USA88(23), 10540–10543 (1991).
   PubMed Web of Science ®Google Scholar
• Nunomura A, Moreira PI, Takeda A, Smith MA, Perry G. Oxidative RNA damage and neurodegeneration. Curr. Med. Chem.14(28), 2968–2975 (2007).
   PubMed Web of Science ®Google Scholar
• Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol.8(1), 57–64 (2008).
   PubMed Web of Science ®Google Scholar
• Scarpa S, Cavallaro RA, D’Anselmi F, Fuso A. Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J. Alzheimers Dis.9(4), 407–414 (2006).
   PubMed Web of Science ®Google Scholar
• Golbe LI. Neurodegeneration in the age of molecular biology. BMJ324(7352), 1467–1468 (2002).
   PubMedGoogle Scholar
• Spillantini MG, Goedert M. The α-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann. NY Acad. Sci.920, 16–27 (2000).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol.213(2), 315–325 (2008).
   PubMed Web of Science ®Google Scholar
• Lei P, Wu WH, Li RW et al. Prevention and promotion effects of apolipoprotein E4 on amylin aggregation. Biochem. Biophys. Res. Commun.368(2), 414–418 (2008).
   PubMedGoogle Scholar
• Sadowski MJ, Pankiewicz J, Scholtzova H et al. Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer’s disease. Proc. Natl Acad. Sci. USA103(49), 18787–18792 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou J, Chen J, Feng Y. Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. J. Huazhong Univ. Sci. Technolog. Med. Sci.26(3), 272–274 (2006).
   PubMedGoogle Scholar
• Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol.156(3), 951–964 (2000).
   PubMed Web of Science ®Google Scholar
• Genis L, Chen Y, Shohami E, Michaelson DM. Tau hyperphosphorylation in apolipoprotein E-deficient and control mice after closed head injury. J. Neurosci. Res.60(4), 559–564 (2000).
   PubMed Web of Science ®Google Scholar
• Gallardo G, Schluter OM, Sudhof TC. A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat. Neurosci.11(3), 301–308 (2008).
   PubMed Web of Science ®Google Scholar
• Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int. Rev. Neurobiol.82, 235–246 (2007).
   PubMed Web of Science ®Google Scholar
• Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und psychiatrisch-gerichtliche Medizin64, 146–148 (1907).
   Google Scholar
• Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol.44(5), 999–1010 (2007).
   PubMed Web of Science ®Google Scholar
• Wojtera M, Sikorska B, Sobow T, Liberski PP. Microglial cells in neurodegenerative disorders. Folia Neuropathol.43(4), 311–321 (2005).
   PubMedGoogle Scholar
• Guerreiro RJ, Santana I, Bras JM, Santiago B, Paiva A, Oliveira C. Peripheral inflammatory cytokines as biomarkers in Alzheimer’s disease and mild cognitive impairment. Neurodegener. Dis.4(6), 406–412 (2007).
   PubMed Web of Science ®Google Scholar
• Koutsilieri E, Scheller C, Grünblatt E, Nara K, Li J, Riederer P. Free radicals in Parkinson’s disease. J. Neurol.249(Suppl. 2), II1–II5 (2002).
   PubMedGoogle Scholar
• Retz W, Gsell W, Munch G, Rosler M, Riederer P. Free radicals in Alzheimer’s disease. J. Neural Transm. Suppl.54, 221–236 (1998).
   PubMedGoogle Scholar
• Nunomura A, Moreira PI, Lee HG et al. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol. Disord. Drug Targets6(6), 411–423 (2007).
   PubMedGoogle Scholar
• Koutsilieri E, Scheller C, Tribl F, Riederer P. Degeneration of neuronal cells due to oxidative stress – microglial contribution. Parkinsonism Relat. Disord.8(6), 401–406 (2002).
   PubMed Web of Science ®Google Scholar
• Tahirovic I, Sofic E, Sapcanin A et al. Reduced brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer’s disease and diabetes mellitus. Neurochem. Res.32(10), 1709–1717 (2007).
   PubMedGoogle Scholar
• de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental Type 3 diabetes: relevance to Alzheimer’s disease. J. Alzheimers Dis.10(1), 89–109 (2006).
   PubMed Web of Science ®Google Scholar
• Leutner S, Czech C, Schindowski K, Touchet N, Eckert A, Muller WE. Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci. Lett.292(2), 87–90 (2000).
   PubMed Web of Science ®Google Scholar
• Schipper HM, Bennett DA, Liberman A et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol. Aging27(2), 252–261 (2006).
   PubMed Web of Science ®Google Scholar
• Brugge K, Nichols S, Saitoh T, Trauner D. Correlations of glutathione peroxidase activity with memory impairment in adults with Down syndrome. Biol. Psychiatry46(12), 1682–1689 (1999).
   PubMed Web of Science ®Google Scholar
• Munch G, Luth HJ, Wong A et al. Crosslinking of α-synuclein by advanced glycation endproducts – an early pathophysiological step in Lewy body formation? J. Chem. Neuroanat.20(3–4), 253–257 (2000).
   PubMed Web of Science ®Google Scholar
• Zigmond MJ, Hastings TG, Perez RG. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat. Disord.8(6), 389–393 (2002).
   PubMed Web of Science ®Google Scholar
• Mandel S, Grünblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strategies in Parkinson’s disease: an update on progress. CNS Drugs17(10), 729–762 (2003).
   PubMed Web of Science ®Google Scholar
• Litvan I, MacIntyre A, Goetz CG et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease and dementia with Lewy bodies: a clinicopathologic study. Arch. Neurol.55(7), 969–978 (1998).
   PubMed Web of Science ®Google Scholar
• Paulus W, Bancher C, Jellinger K. Interrater reliability in the neuropathologic diagnosis of Alzheimer’s disease. Neurology42(2), 329–332 (1992).
   PubMedGoogle Scholar
• Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J. Neurol. Sci.95(3), 239–258 (1990).
   PubMed Web of Science ®Google Scholar
• Borroni B, Premi E, Di Luca M, Padovani A. Combined biomarkers for early Alzheimer disease diagnosis. Curr. Med. Chem.14(11), 1171–1178 (2007).
   PubMedGoogle Scholar
• Marksteiner J, Hinterhuber H, Humpel C. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer’s disease: β-amyloid(1–42), tau, phospho-tau-181 and total protein. Drugs Today (Barc.), 43(6), 423–431 (2007).
   PubMedGoogle Scholar
• Blennow K, Zetterberg H, Minthon L et al. Longitudinal stability of CSF biomarkers in Alzheimer’s disease. Neurosci. Lett.419(1), 18–22 (2007).
   PubMedGoogle Scholar
• Martinez M, Fernandez E, Frank A, Guaza C, de la Fuente M, Hernanz A. Increased cerebrospinal fluid cAMP levels in Alzheimer’s disease. Brain Res.846(2), 265–267 (1999).
   PubMed Web of Science ®Google Scholar
• Simonsen AH, McGuire J, Hansson O et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol.64(3), 366–370 (2007).
   PubMedGoogle Scholar
• Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology70(23), 2212–2218 (2008).
   PubMedGoogle Scholar
• Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov.6(4), 295–303 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol.129(4), 526–529 (2008).
   PubMed Web of Science ®Google Scholar
• Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker? J. Cell Mol. Med.12(4), 1094–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am. J. Epidemiol.167(1), 90–95 (2008).
   PubMed Web of Science ®Google Scholar
• Bibl M, Esselmann H, Mollenhauer B et al. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J. Neurochem.103(2), 467–474 (2007).
   PubMed Web of Science ®Google Scholar
• Schipper HM, Chertkow H, Mehindate K, Frankel D, Melmed C, Bergman H. Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD. Neurology54(6), 1297–1304 (2000).
   PubMed Web of Science ®Google Scholar
• Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer’s disease. Brain129(Pt 11), 3042–3050 (2006).
   PubMed Web of Science ®Google Scholar
• Lovestone S, Guntert A, Hye A, Lynham S, Thambisetty M, Ward M. Proteomics of Alzheimer’s disease: understanding mechanisms and seeking biomarkers. Expert Rev. Proteomics4(2), 227–238 (2007).
   PubMed Web of Science ®Google Scholar
• Goldknopf IL. Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev. Proteomics5(1), 1–8 (2008).
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11), 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Grünblatt E, Schlößer R, Fischer P et al. Oxidative stress related markers in the “VITA” and the centenarian projects. Neurobiol. Aging26(4), 429–438 (2005).
   PubMedGoogle Scholar
• Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol. Aging28(12), 1795–1809 (2007).
   PubMed Web of Science ®Google Scholar
• Kalman J, Kitajka K, Pakaski M et al. Gene expression profile analysis of lymphocytes from Alzheimer’s patients. Psychiatr. Genet.15(1), 1–6 (2005).
   PubMed Web of Science ®Google Scholar
• Matsubara T, Funato H, Kobayashi A, Nobumoto M, Watanabe Y. Reduced glucocorticoid receptor α expression in mood disorder patients and first-degree relatives. Biol. Psychiatry59(8), 689–695 (2006).
   PubMed Web of Science ®Google Scholar
• Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry28(3), 559–576 (2004).
   PubMed Web of Science ®Google Scholar
• Burczynski ME, Dorner AJ. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics7(2), 187–202 (2006).
   PubMed Web of Science ®Google Scholar
• Le W, Pan T, Huang M et al. Decreased NURR1 gene expression in patients with Parkinson’s disease. J. Neurol. Sci.273(1–2), 29–33 (2008).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Eklund AC, Morse LJ et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc. Natl Acad. Sci. USA104(3), 955–960 (2007).
   PubMed Web of Science ®Google Scholar
• Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet.141(3), 261–268 (2006).
   Web of Science ®Google Scholar
• Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med.147(3), 126–132 (2006).
   PubMed Web of Science ®Google Scholar
• Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer’s disease). Pharmacogenomics J.7(1), 10–28 (2007).
   PubMed Web of Science ®Google Scholar
• Pearson JV, Huentelman MJ, Halperin RF et al. Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am. J. Hum. Genet.80(1), 126–139 (2007).
   PubMed Web of Science ®Google Scholar
• Evangelou E, Maraganore DM, Ioannidis JP. Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease. PLoS ONE2(2), e196 (2007).
   Google Scholar
• Coon KD, Myers AJ, Craig DW et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J. Clin. Psychiatry68(4), 613–618 (2007).
   PubMed Web of Science ®Google Scholar